Full Text View
Tabular View
No Study Results Posted
Related Studies
Race, Ethnicity, and Diffuse Parenchymal Lung Disease
This study is currently recruiting participants.
Verified by Columbia University, February 2009
First Received: March 27, 2007   Last Updated: February 2, 2009   History of Changes
Sponsored by: Columbia University
Information provided by: Columbia University
ClinicalTrials.gov Identifier: NCT00453713
  Purpose

The purpose of this study is to identify factors that contribute to higher mortality rates among blacks and Hispanics with diffuse parenchymal lung disease.


Condition
Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease
Diffuse Parenchymal Lung Disease

Study Type: Observational
Study Design: Cohort, Prospective
Official Title: Determinants of Outcome in Diffuse Parenchymal Lung Disease

Resource links provided by NLM:


Further study details as provided by Columbia University:

Biospecimen Retention:   Samples With DNA

Biospecimen Description:

Estimated Enrollment: 400
Study Start Date: February 2007
Estimated Study Completion Date: January 2012
Detailed Description:

It is well known that both socioeconomic and biological factors may contribute to race- and ethnicity-based health disparities. Black and Hispanic Americans have worse access to healthcare services and tend to receive care from physicians who cannot themselves access the same services for their patients that physicians who care for white patients can. These factors may play important roles in the development and maintenance of health disparities. In addition, biological differences may contribute to disparities. We propose to identify factors that explain survival disparities in a group of lung diseases called diffuse parenchymal lung diseases (DPLDs), including a severe form of DPLD called idiopathic pulmonary fibrosis (IPF). We will follow patients with DPLD at our center and measure both social and biological factors to try to identify the factors that lead to survival disparities between races. Results of this study will be used to design clinical trials aimed at reducing these disparities.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Diffuse parenchymal lung disease

Criteria

Inclusion Criteria:

  • Diagnosis of IPF or other DPLD according to ATS criteria
  • Signed informed consent

Exclusion Criteria:

  • None
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00453713

Contacts
Contact: Nisha A Philip, M.B.B.S. (212) 305-7720 np2173@columbia.edu

Locations
United States, New York
Columbia University Medical Center Recruiting
New York, New York, United States, 10032
Principal Investigator: David J Lederer, M.D.            
Sponsors and Collaborators
Columbia University
Investigators
Principal Investigator: David J Lederer, M.D. Columbia University
  More Information

No publications provided

Responsible Party: Columbia University ( David Lederer )
Study ID Numbers: AAAB8771
Study First Received: March 27, 2007
Last Updated: February 2, 2009
ClinicalTrials.gov Identifier: NCT00453713     History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by Columbia University:
Idiopathic pulmonary fibrosis
Interstitial lung disease
Diffuse parenchymal lung disease
Health disparities

Study placed in the following topic categories:
Lung Diseases, Interstitial
Respiratory Tract Diseases
Fibrosis
Idiopathic Pulmonary Fibrosis
Lung Diseases
Pulmonary Fibrosis

Additional relevant MeSH terms:
Lung Diseases, Interstitial
Pathologic Processes
Respiratory Tract Diseases
Fibrosis
Lung Diseases
Pulmonary Fibrosis

ClinicalTrials.gov processed this record on September 10, 2009